Cilostazol for treatment of cerebral infarction

References

• Sacco RL, Kasner SE, Broderick JP, et al. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44:2064–2089.
   PubMed Web of Science ®Google Scholar
• Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367:1747–1757.
   PubMed Web of Science ®Google Scholar
• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study. Lancet. 2010;380:2095–2128.
   Web of Science ®Google Scholar
• Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study. Lancet. 2010;380:2197–2223.
   Web of Science ®Google Scholar
• Murray JW, Edmonds BT, Liu G, et al. Bundling of actin filaments by elongation factor 1 alpha inhibits polymerization at filament ends. J Cell Biol. 1996;135:1309–1321.
   PubMed Web of Science ®Google Scholar
• Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:2160–2236.
   PubMed Web of Science ®Google Scholar
• Dhamoon MS, Sciacca RR, Rundek T, et al. Recurrent stroke and cardiac risks after first ischemic stroke: the Northern Manhattan Study. Neurology. 2006;66:641–646.
   PubMed Web of Science ®Google Scholar
• Graham GD. Secondary stroke prevention: from guidelines to clinical practice. J Natl Med Assoc. 2008;100:1125–1137.
   PubMed Web of Science ®Google Scholar
• Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts)developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315–2381.
   PubMed Web of Science ®Google Scholar
• Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:2160–2236.
   PubMed Web of Science ®Google Scholar
• Society TJS. Japanese guidelines for the management of stroke. 2015.
   Google Scholar
• Ito H, Uehara K, Matsumoto Y, et al. Cilostazol inhibits accumulation of triglyceride in aorta and platelet aggregation in cholesterol-fed rabbits. PLoS One. 7:e39374.
   PubMed Web of Science ®Google Scholar
• Yamamoto H, Takahashi K, Watanabe H, et al. Evaluation of the antiplatelet effects of cilostazol, a phosphodiesterase 3 inhibitor, by VASP phosphorylation and platelet aggregation. Circ J. 2008;72:1844–1851.
   PubMed Web of Science ®Google Scholar
• Hayashi S, Morishita R, Matsushita H, et al. Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21. Hypertension. 2000;35:237–243.
   PubMed Web of Science ®Google Scholar
• Aoki M, Morishita R, Matsushita H, et al. Inhibition of the p53 tumor suppressor gene results in growth of human aortic vascular smooth muscle cells. Potential role of p53 in regulation of vascular smooth muscle cell growth. Hypertension. 1999;34:192–200.
   PubMed Web of Science ®Google Scholar
• Agrawal NK, Maiti R, Dash D, et al. Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients. Pharmacol Res. 2007;56:118–123.
   PubMed Web of Science ®Google Scholar
• Gresele P, Momi S, Falcinelli E. Anti-platelet therapy: phosphodiesterase inhibitors. Br J Clin Pharmacol. 2011;72:634–646.
   PubMed Web of Science ®Google Scholar
• Umebayashi R, Uchida HA, Kakio Y, et al. Cilostazol attenuates angiotensin II-induced abdominal aortic aneurysms but not atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2018;38:903–912.
   PubMed Web of Science ®Google Scholar
• Choi BR, Kim DH, Back DB, et al. Characterization of white matter injury in a rat model of chronic cerebral hypoperfusion. Stroke. 2016;47:542–547.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Zhang N, Liu M, et al. Cilostazol protects against brain white matter damage and cognitive impairment in a rat model of chronic cerebral hypoperfusion. Stroke. 2006;37:1539–1545.
   PubMed Web of Science ®Google Scholar
• Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet. 2014;383:245–254.
   PubMed Web of Science ®Google Scholar
• Feigin VL, Norrving B, Mensah GA. Global burden of stroke. Circ Res. 2017;120:439–448.
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Virani SS, Callaway CW. et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137:e67–e492.
   PubMed Web of Science ®Google Scholar
• Sudo T, Tachibana K, Toga K, et al. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem Pharmacol. 2000;59:347–356.
   PubMed Web of Science ®Google Scholar
• Liu Y, Shakur Y, Yoshitake M, et al. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev. 2001;19:369–386.
   PubMed Web of Science ®Google Scholar
• Hiratsuka M, Hinai Y, Sasaki T, et al. Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol. Drug Metab Dispos. 2007;35:1730–1732.
   PubMed Web of Science ®Google Scholar
• Yoo HD, Park SA, Cho HY, et al. Influence of CYP3A and CYP2C19 genetic polymorphisms on the pharmacokinetics of cilostazol in healthy subjects. Clin Pharmacol Ther. 2009;86:281–284.
   PubMed Web of Science ®Google Scholar
• Akiyama H, Kudo S, Shimizu T. The absorption, distribution and excretion of a new antithrombotic and vasodilating agent, cilostazol, in rat, rabbit, dog and man. Arzneimittelforschung. 1985;35:1124–1132.
   PubMed Web of Science ®Google Scholar
• Pearce L, Ghosh J, Counsell A, et al. Cilostazol and peripheral arterial disease. Expert Opin Pharmacother. 2008;9:2683–2690.
   PubMed Web of Science ®Google Scholar
• Al-Qudah ZA, Hassan AE, Qureshi AI. Cilostazol in patients with ischemic stroke. Expert Opin Pharmacother. 2011;12:1305–1315.
   PubMed Web of Science ®Google Scholar
• Galyfos G, Sianou A. Cilostazol for secondary prevention of stroke: should the guidelines perhaps be extended? Vasc Specialist Int. 2017;33:89–92.
   PubMedGoogle Scholar
• Kimura Y, Tani T, Kanbe T, et al. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung. 1985;35:1144–1149.
   PubMed Web of Science ®Google Scholar
• Gotoh F, Tohgi H, Hirai S, et al. Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis. 2000;9:147–157.
   PubMedGoogle Scholar
• Goto S. Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl. 2005;6:3–11.
   PubMed Web of Science ®Google Scholar
• Shichinohe H, Tan C, Abumiya T, et al. Neuroprotective effects of cilostazol are mediated by multiple mechanisms in a mouse model of permanent focal ischemia. Brain Res. 2015;1602:53–61.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Ishikawa T, Hagiwara M, et al. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology. 1988;36:313–320.
   PubMed Web of Science ®Google Scholar
• Zhao H, Quilley J, Montrose DC, et al. Differential effects of phosphodiesterase PDE-3/PDE-4-specific inhibitors on vasoconstriction and cAMP-dependent vasorelaxation following balloon angioplasty. Am J Physiol Heart Circ Physiol. 2007;292:H2973–2981.
   PubMed Web of Science ®Google Scholar
• Wu SN, Liu SI, Huang MH. Cilostazol, an inhibitor of type 3 phosphodiesterase, stimulates large-conductance, calcium-activated potassium channels in pituitary GH3 cells and pheochromocytoma PC12 cells. Endocrinology. 2004;145:1175–1184.
   PubMed Web of Science ®Google Scholar
• Fujinaga K, Onoda K, Yamamoto K, et al. Locally applied cilostazol suppresses neointimal hyperplasia by inhibiting tenascin-C synthesis and smooth muscle cell proliferation in free artery grafts. J Thorac Cardiovasc Surg. 2004;128:357–363.
   PubMed Web of Science ®Google Scholar
• Takahashi S, Oida K, Fujiwara R, et al. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol. 1992;20:900–906.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Onoda K, Sawada Y, et al. Locally applied cilostazol suppresses neointimal hyperplasia and medial thickening in a vein graft model. Ann Thorac Cardiovasc Surg. 2007;13:322–330.
   PubMedGoogle Scholar
• Hong KW, Lee JH, Kima KY, et al. Cilostazol: therapeutic potential against focal cerebral ischemic damage. Curr Pharm Des. 2006;12:565–573.
   PubMed Web of Science ®Google Scholar
• Ishiguro M, Hara H. Protective effects of cilostazol against transient focal cerebral ischemia and hemorrhagic transformation. Yakugaku Zasshi. 2011;131:513–521.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Masui Y, Ohnuki M, et al. Induction of metallothionein synthesis by cilostazol in mice and in human cultured neuronal cell lines. Biol Pharm Bull. 2007;30:791–794.
   PubMed Web of Science ®Google Scholar
• Edrissi H, Schock SC, Cadonic R, et al. Cilostazol reduces blood brain barrier dysfunction, white matter lesion formation and motor deficits following chronic cerebral hypoperfusion. Brain Res. 2016;1646:494–503.
   PubMed Web of Science ®Google Scholar
• Takagi T, Imai T, Mishiro K, et al. Cilostazol ameliorates collagenase-induced cerebral hemorrhage by protecting the blood-brain barrier. J Cereb Blood Flow Metab. 2017;37:123–139.
   PubMed Web of Science ®Google Scholar
• Kim JS, Lee KS, Kim YI, et al. A randomized crossover comparative study of aspirin, cilostazol and clopidogrel in normal controls: analysis with quantitative bleeding time and platelet aggregation test. J Clin Neurosci. 2004;11:600–602.
   PubMed Web of Science ®Google Scholar
• Takazakura EO, Hamamatsu K. Effect of cilostazol (pletal) on serum lipid levels of diabetic patients. Jpn Pharmacol Ther. 1989;17:311–315.
   Google Scholar
• Elam MB, Heckman J, Crouse JR, et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol. 1998;18:1942–1947.
   PubMed Web of Science ®Google Scholar
• Nakamura N, Osawa H, Yamabe H, et al. Effects of cilostazol on lipid and fatty acid metabolism. Clin Exp Med. 2005;4:170–173.
   PubMed Web of Science ®Google Scholar
• Shinohara Y, Katayama Y, Uchiyama S, et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol. 2010;9:959–968.
   PubMed Web of Science ®Google Scholar
• Huang Y, Cheng Y, Wu JL, et al. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol. 2008;7:494–499.
   PubMed Web of Science ®Google Scholar
• Toyoda K, Uchiyama S, Hoshino H, et al. Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial. Int J Stroke. 2015;10:253–258.
   PubMed Web of Science ®Google Scholar
• Shi L, Pu J, Xu L, et al. The efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population–an updated meta-analysis. BMC Neurol. 2014;14:251.
   PubMed Web of Science ®Google Scholar
• Xie W, Zheng F, Zhong B, et al. Long-term antiplatelet mono- and dual therapies after ischemic stroke or transient ischemic attack: network meta-analysis. J Am Heart Assoc. 2015;4:e002259.
   PubMed Web of Science ®Google Scholar
• Tan L, Margaret B, Zhang JH, et al. Efficacy and safety of cilostazol therapy in ischemic stroke: a meta-analysis. J Stroke Cerebrovasc Dis. 2015;24:930–938.
   PubMed Web of Science ®Google Scholar
• Niu PP, Guo ZN, Jin H, et al. Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis. BMJ Open. 2016;6:e009013.
   PubMed Web of Science ®Google Scholar
• Wang W, Zhang L, Liu W, et al. Antiplatelet agents for the secondary prevention of ischemic stroke or transient ischemic attack: a network meta-analysis. J Stroke Cerebrovasc Dis. 2016;25:1081–1089.
   PubMed Web of Science ®Google Scholar
• Kamal AK, Naqvi I, Husain MR, et al. Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. Cochrane Database Syst Rev. 2011;CD008076.
   PubMed Web of Science ®Google Scholar
• Niki T, Mori H. Phase I study of cilostazol. Safety evaluation at increasing single doses in healthy volunteers. Arzneimittelforschung. 1985;35:1173–1185.
   PubMed Web of Science ®Google Scholar
• Prickaerts J, Heckman PRA, Blokland A. Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer’s disease. Expert Opin Investig Drugs. 2017;26:1033–1048.
   PubMed Web of Science ®Google Scholar
• Saito S, Kojima S, Oishi N, et al. A multicenter, randomized, placebo-controlled trial for cilostazol in patients with mild cognitive impairment: the COMCID study protocol. Alzheimers Dement (N Y). 2016;2:250–257.
   PubMedGoogle Scholar
• Tuttolomondo A, Pecoraro R, Simonetta I, et al. Neurological complications of Anderson-Fabry disease. Curr Pharm Des. 2013;19:6014–6030.
   PubMed Web of Science ®Google Scholar
• Tuttolomondo A, Pecoraro R, Simonetta I, et al. Anderson-Fabry disease: a multiorgan disease. Curr Pharm Des. 2013;19:5974–5996.
   PubMed Web of Science ®Google Scholar